Genzyme wins U.S. approval for bone marrow transplant drug

12/15/2008 | Bloomberg · Reuters

The FDA approved Genzyme's Mozobil, a drug capable of boosting the number of bone marrow stem cells that can be used for transplant. The treatment is intended for people with non-Hodgkin's lymphoma or multiple myeloma. The clearance covers Mozobil's use with Amgen's Neupogen and other agents designed to trigger the growth and circulation of bone marrow cells in blood.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX